title: Deuterated drugs draw heavier backing.
authors.forename: Asher
authors.initials: A
authors.lastname: Mullard
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000494:pharmacology; D002986:Clinical Trials as Topic; D003903:Deuterium / Q000494:pharmacology*; D017277:Drug Approval; D015195:Drug Design; D006207:Half-Life; D006801:Humans; D019965:Neurocognitive Disorders / Q000188:drug therapy / Q000378:metabolism; D018570:Risk Assessment; D013747:Tetrabenazine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000494:pharmacology; D050493:Vesicular Monoamine Transport Proteins / Q000037:antagonists & inhibitors
chemical_list: D018759:Adrenergic Uptake Inhibitors; D050493:Vesicular Monoamine Transport Proteins; D003903:Deuterium; D013747:Tetrabenazine